Vaxcyte (PCVX): Reassessing Valuation After OPUS Phase 3 Trial Start for Next-Generation Pneumococcal Vaccine

Simply Wall St.12-10

Vaxcyte (PCVX) just hit a key milestone by dosing the first participants in its OPUS Phase 3 trial of VAX-31, a head-to-head study against current adult pneumococcal vaccines that supports its future ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590322194?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-10 01:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590322194","market":"nz","top_or_hot":-1,"title":"Vaxcyte (PCVX): Reassessing Valuation After OPUS Phase 3 Trial Start for Next-Generation Pneumococcal Vaccine","media":"Simply Wall St.","content":"<div>\n<p>Vaxcyte (PCVX) just hit a key milestone by dosing the first participants in its OPUS Phase 3 trial of VAX-31, a head-to-head study against current adult pneumococcal vaccines that supports its future ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte (PCVX): Reassessing Valuation After OPUS Phase 3 Trial Start for Next-Generation Pneumococcal Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte (PCVX): Reassessing Valuation After OPUS Phase 3 Trial Start for Next-Generation Pneumococcal Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-10 01:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaxcyte (PCVX) just hit a key milestone by dosing the first participants in its OPUS Phase 3 trial of VAX-31, a head-to-head study against current adult pneumococcal vaccines that supports its future ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial","article_id":"2590322194","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590322194","pubTimestamp":1765301329,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vaxcyte (PCVX) just hit a key milestone by dosing the first participants in its OPUS Phase 3 trial of VAX-31, a head-to-head study against current adult pneumococcal vaccines that supports its future approval plans.\nSee our latest analysis for Vaxcyte.\nThat backdrop helps explain why, even with a sharp year to date share price return of minus 44.56 percent and a one year total shareholder return of minus 49.84 percent, the recent three month share price rebound of 41.14 percent suggests...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","OPUS":"OPUS MAGNUM AMERIS, INC.","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","PCVX":"Vaxcyte, Inc.","BK4139":"生物科技"},"translate_title":"Vaxcyte(PCVX)：下一代肺炎球菌疫苗OPUS 3期试验开始后重新评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":1.5,"OPUS":1.5},"content_text":"Vaxcyte (PCVX) just hit a key milestone by dosing the first participants in its OPUS Phase 3 trial of VAX-31, a head-to-head study against current adult pneumococcal vaccines that supports its future approval plans. See our latest analysis for Vaxcyte. That backdrop helps explain why, even with a sharp year to date share price return of minus 44.56 percent and a one year total shareholder return of minus 49.84 percent, the recent three month share price rebound of 41.14 percent suggests sentiment is cautiously rebuilding around Vaxcyte at 46.18 dollars a share. If this kind of late stage pipeline momentum has your attention, it could be a good moment to explore other specialist names in healthcare stocks for fresh ideas. With shares still trading at barely half of Wall Street’s target despite recent momentum, is Vaxcyte a mispriced late stage vaccine contender, or are investors already baking in every ounce of future growth? AdvertisementPrice-To-Book of 2.1x: Is it justified? On a price to book basis, Vaxcyte trades at 2.1 times, a notable discount to many biotech peers despite its recent share price recovery. The price to book ratio compares a company’s market value to the net assets on its balance sheet. This can be a useful lens for pre revenue, loss making biotech names where earnings metrics are not yet meaningful. For Vaxcyte, this yardstick helps frame what investors are paying today for its cash, platform and late stage vaccine pipeline. Relative to its direct peer set, where the average price to book stands at 12.3 times, Vaxcyte’s 2.1 times multiple indicates that the market is assigning a much lower premium to its assets than to competitors. The same pattern holds at the broader industry level, with the US biotech sector on 2.7 times book. This underscores that Vaxcyte currently screens as inexpensive on this commonly watched valuation gauge. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 2.1x (UNDERVALUED) However, setbacks in late stage trials or further dilution to fund its cash-burning pipeline could quickly erode confidence in the current recovery story. Find out about the key risks to this Vaxcyte narrative.  Build Your Own Vaxcyte Narrative If you would rather dig into the numbers yourself and shape your own story around Vaxcyte, you can build a tailored view in minutes: Do it your way. A great starting point for your Vaxcyte research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? Before the next catalyst hits, give yourself options by scanning other opportunities on Simply Wall Street’s Screener so your portfolio is ready, not reactive.  Capture early momentum in smaller names by hunting through these 3593 penny stocks with strong financials that already back their stories with real financial strength. Ride structural shifts in technology by targeting these 27 AI penny stocks poised to benefit from surging demand for automation and intelligent software. Lock in potential mispricings by focusing on these 908 undervalued stocks based on cash flows where robust cash flows are not yet fully reflected in market expectations.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590322194","isCrawlerRequest":true}